Using Real World Evidence to Describe Pulmonary Arterial Hypertension Treatment Patterns, Healthcare Resource Utilization, and Costs Associated with PDE-5 Inhibitor Monotherapy
**Background:** Pulmonary arterial hypertension (PAH) is described by proliferation of small pulmonary arteries leading to increased pulmonary vascular resistance, right ventricular failure, and death. Research confirms long-term improvement in composite morbidity and mortality endpoints on some end...
| Auteurs principaux: | , , , , , , |
|---|---|
| Format: | Article |
| Langue: | English |
| Publié: |
Columbia Data Analytics, LLC
2018-01-01
|
| Collection: | Journal of Health Economics and Outcomes Research |
| Accès en ligne: | https://doi.org/10.36469/9812 |